Angion Biomedica Corp   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Uniondale NY United States (1998)
Status: Acquired by Elicio Therapeutics (2023)

Organization Overview

First Clinical Trial
2010
NCT01286727
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Angion Biomedica | Angion Biomedica Corp

Active Ingredients

Drugs in Phase 3 Trials (1)

ang-3777 (9 trials)

Drugs in Phase 2 Trials (2)

ang3070 (3 trials)

sodium chloride (2 trials)

Drugs in Phase 1 Trials (1)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 2)

Delayed Graft Function (Phase 3)

Idiopathic Pulmonary Fibrosis (Phase 1)

Infarction (Phase 2)

Myocardial Infarction (Phase 2)

Pneumonia (Phase 2)

Pulmonary Fibrosis (Phase 1)

ST Elevation Myocardial Infarction (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 4